

IN THE CLAIMS:

1. (Amended) A method of treating or preventing sexual dysfunction which comprises administering to a subject suffering or liable to suffer therefrom and in need of treatment or prevention an effective amount of a bombesin receptor antagonist.

Claims 2 –3 and 11-13: please delete.

- 10 14. (Amended) The method of claim [22] 1, wherein [the vasodilator is selected from] *the bombesin receptor antagonist is administered in combination with* alprostadil or phentolamine.

Claim 15: please delete.

- 15 16. (Amended) The method of claim [22] 1, wherein [the vasodilator is] *the bombesin receptor antagonist is administered in combination with* a compound that promotes production of NO.

- 20 21. (Amended) The method of claim [11] 1, wherein the bombesin receptor antagonist and [the] a vasodilator are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the vasodilator and a pharmaceutically acceptable carrier or diluent.

- 25 Please add the following new claims:

24. *The method of claim 5, wherein the sexual dysfunction is hypoactive sexual desire disorder.*

- 30 25. *The method of claim 5, wherein the sexual dysfunction is a sexual arousal disorder.*

26. *The method of claim 5, wherein the sexual dysfunction is an orgasmic disorder or anorgasmic.*
- 5 27. *The method of claim 5, wherein the sexual dysfunction is sexual pain disorder.*
28. *The method of claim 5, wherein the subject is receiving an antidepressant or antihypertensive.*
- 10 29. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the clitoris or vagina or on lubricant secretion.*
- 15 30. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDES inhibitor.*
31. *The method of claim 30, wherein the PDES inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.*
- 20 32. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.*
33. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.*
- 25 34. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an oestrogen.*
- 30 35. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.*

36. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.*
- 5 37. *The method of claim 6, wherein the sexual dysfunction is erectile dysfunction.*
38. *The method of claim 6, wherein the sexual dysfunction is psychogenic.*
39. *The method of claim 6, wherein the sexual dysfunction is drug-induced.*
- 10 40. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the penis.*
- 15 41. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.*
42. *The method of claim 6, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.*
- 20 43. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.*
44. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.*
- 25 45. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.*
- 30 46. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.*